Trade Report: Today, Aclaris Therapeutics Inc. (ACRS) Earns Outperform Rating from Analysts at Leerink Swann

Today, Aclaris Therapeutics Inc. (ACRS) Earns Outperform Rating from Analysts at Leerink Swann

Analysts at Leerink Swann started coverage on shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) in a report released on Tuesday. The firm set an “outperform” rating on the stock.

ACRS has been the topic of several other research reports. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 18th. Jefferies Group upped their target price on Aclaris Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Monday, September 19th. Finally, JMP Securities initiated coverage on Aclaris Therapeutics in a report on Friday, September 30th. They issued an “outperform” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Aclaris Therapeutics presently has an average rating of “Buy” and an average target price of $32.50.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up 4.21% on Tuesday, reaching $29.22. 32,872 shares of the company’s stock were exchanged. The company’s market capitalization is $626.24 million. Aclaris Therapeutics has a 12 month low of $14.12 and a 12 month high of $33.88. The firm’s 50 day moving average price is $23.20 and its 200-day moving average price is $21.47.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.16. On average, equities analysts anticipate that Aclaris Therapeutics will post ($2.38) EPS for the current year.

In related news, insider Kamil Ali-Jackson sold 3,912 shares of the stock in a transaction that occurred on Wednesday, October 26th. The stock was sold at an average price of $21.83, for a total value of $85,398.96. Following the transaction, the insider now owns 79,869 shares in the company, valued at $1,743,540.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 907,828 shares of the stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $23.03, for a total value of $20,907,278.84. The disclosure for this sale can be found here. 46.40% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in ACRS. Rock Springs Capital Management LP increased its position in Aclaris Therapeutics by 1.6% in the third quarter. Rock Springs Capital Management LP now owns 1,016,000 shares of the company’s stock worth $26,020,000 after buying an additional 16,000 shares in the last quarter. FIL Ltd purchased a new position in Aclaris Therapeutics during the second quarter worth approximately $13,801,000. Vanguard Group Inc. increased its position in Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock worth $7,743,000 after buying an additional 249,888 shares in the last quarter. BlackRock Fund Advisors increased its position in Aclaris Therapeutics by 13.6% in the third quarter. BlackRock Fund Advisors now owns 266,552 shares of the company’s stock worth $6,826,000 after buying an additional 31,856 shares in the last quarter. Finally, State Street Corp increased its position in Aclaris Therapeutics by 64.8% in the second quarter. State Street Corp now owns 120,010 shares of the company’s stock worth $2,217,000 after buying an additional 47,179 shares in the last quarter. Hedge funds and other institutional investors own 72.10% of the company’s stock.

About Aclaris Therapeutics

Related posts

Leave a Comment